Skip to main content
ARS Home » Southeast Area » Athens, Georgia » U.S. National Poultry Research Center » Exotic & Emerging Avian Viral Diseases Research » Research » Publications at this Location » Publication #287697

Title: New USDA licensed avian influenza vaccine (rHVT-AI) for protection against H5 avian influenza and usage discussion

item Kapczynski, Darrell

Submitted to: Meeting Abstract
Publication Type: Proceedings
Publication Acceptance Date: 10/20/2012
Publication Date: 10/23/2012
Citation: Kapczynski, D.R. 2012. New USDA licensed avian influenza vaccine (rHVT-AI) for protection against H5 avian influenza and usage discussion. In: Proceedings of US Animal Health Association-Committee on Transmissible Diseases of Poultry and other Avian Species, Greensboro, NC, October 22-23, 2012. p.139.

Interpretive Summary:

Technical Abstract: Recently, a new avian influenza vaccine was licensed by USDA for use in the United States for protection of commercial poultry. The vaccine is a recombinant herpes virus of turkeys expressing the hemagglutinin gene of an H5 subtype avian influenza virus belonging to the 2.2 clade of the H5N1 highly pathogenic avian influenza viruses of Southeast Asian lineage. Vaccine efficacy studies have demonstrated protection of chickens and turkeys against homologous and heterologous clade challenges, and reduce viral shedding and thus transmission potential. The parameters of when and under what conditions this vaccine might be employed are the subject of discussion among state veterinarians. In addition the impact of its use on global trade is also under consideration. Application of this vaccine does allow for differentiation of infected from vaccinated animals, the so called DIVA strategy, with current molecular and antibody tests. However, the duration of vaccine replication and its potential impact on the perception of influenza-free status of US poultry remain unknown.